LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company,
announced the closing of an underwritten public offering of 4,312,500
shares of its common stock at a price to the public of $40.00 per share.
The shares of common stock issued in the offering included 562,500
shares of common stock issued upon the exercise in full by the
underwriters of their option to purchase additional shares. The net
proceeds from the offering were approximately $162 million, after
deducting the underwriting discounts and commissions and estimated
offering expenses payable by the Company.
Citigroup and J.P. Morgan acted as lead book-running managers, Credit
Suisse acted as joint book-running manager and BofA Merrill Lynch acted
as lead manager for the offering. Stifel acted as co-manager for the
offering.
The offering was made pursuant to an automatically effective shelf
registration statement filed with the Securities and Exchange Commission
(SEC) on January 20, 2015. A prospectus supplement describing the terms
of the offering has been filed with the SEC and is available on the
SEC’s website at www.sec.gov.
Copies of the prospectus supplement and the accompanying prospectus
relating to the offering may be obtained by contacting Citigroup Global
Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, or by phone at (800) 831-9146; J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, New York 11717, or by phone at (866) 803-9204;
or Credit Suisse, Attention: Prospectus Department, One Madison Avenue,
New York, NY 10010, by telephone at (800) 221-1037, or by email at newyork.prospectus@credit-suisse.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
Contact: